- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00976430
Autologous Mesenchymal Stem Cell Transplant for Parkinson's Disease
To Study the Safety and Efficacy of Bone Marrow Derived Mesenchymal Stem Cells Transplant in Parkinson's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Parkinson's disease, a neurodegenerative disorder, still at its best can only be controlled by medical or surgical treatment. For more than two decades various groups have tried using modified cell transplants for curing this disease. Earlier results with use of fetal mesencephalic cell transplant were encouraging, but this had to be discontinued due to severe side effects.
Current interest, in the use of Mesenchymal stem cells as a pluripotent cell for developing neural cells has been the background for this study. Reliance Life sciences had found encouraging results with the use of human MSCs in Rat model of PD. Based on this and other data, Jaslok Hospital and Research Centre has initiated a pilot study to investigate the efficacy of Autologous MSCs in treating advanced PD. This cells will be harvested from bone marrow, processed at RLS laboratory and transplanted by stereotactic techniques into the striatum of the patient.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400026
- Jaslok Hospital and Research Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Male or female between 35-70 years of age.
- Patient with current diagnosis of PD with motor complications (as confirmed by neurologist) as per the standard criteria and guidelines.
- Patients with at least 5 years since the disease.
- Responsiveness to Levodopa or dopa agonist. This is defined as improvement between Off and On UPDRS by at least 33% of the Motor UPDRS.
- PD of Stage 2.5, 3 & 4 of HOEHN & YAHR staging.
- Stable Parkinsonian medications for the 60 days prior to the surgical therapy.
- MRI not showing gross atrophy or any other pathology of brain.
- Patients with score less than 19 for the Montgomery-Asberg Rating Scale (MADRS) for Depression.
- NO Significant cognitive impairment.MMSE > 24.
- The participant is able to comply with and understand the required visit schedule and all required tests and procedures.
- The participant (and/or LAR) must sign an informed consent.
Exclusion Criteria:
- History of intracranial surgeries or implantation of a device for Parkinson's disease two years prior to treatment.
- History of psychiatric disorders like schizophrenia or psychotic disorders.
- History of other malignancy, with the exception of treated cutaneous squamous cell or basal cell carcinoma, within 5 years.
- Contraindication for MRI
- General medical contraindications for surgery like coagulopathy
- Subjects with abnormal hematology and chemistry values, unless the out of range values are clinically significant with respect to general surgery.
- Severe skin infection or osteomyelitis at the site of bone marrow aspiration potentially limiting the procedure.
- Positive test results for HIV.
- History of drug or alcohol abuse
- Pregnant or nursing women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Therapy for Parkinson's disease
Stem cell derived from the bone marrow of the patient will be stereotactically transplanted in the striatum.These stem cell are the expected to grow up into dopamine secreting neural cells.
|
Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Improvement in clinical condition of the patient assessed using UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) and Time Tests.
Time Frame: Up to 18 months from the day of stem cell transplant.
|
Up to 18 months from the day of stem cell transplant.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Paresh k Doshi, MCh, Incharge Stereotactic and functional Neurosurgery,Jaslok Hospital and Research Centre.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- JHC525
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada
Clinical Trials on Autologous Bone marrow derived stem cells transplant
-
TCA Cellular TherapySuspendedAmyotrophic Lateral SclerosisUnited States
-
Al-Azhar UniversityHassan , Hosny , M.D. M.Sc; Samour , Hany M.D. M.Sc; Ismail , Mahmoud M.D. M.Sc; Higazy , Hasan M.D. M.Sc and other collaboratorsUnknownAge Related Macular DegenerationEgypt
-
Silesian School of MedicineMinistry of Science and Higher Education, PolandCompletedMyocardial InfarctionPoland
-
TCA Cellular TherapySuspendedSpinal Cord InjuryUnited States
-
Hadassah Medical OrganizationCompletedMultiple Sclerosis
-
University Hospital, Clermont-FerrandCompletedIschemic Heart DiseaseFrance
-
Novo Cellular Medicine Institute LLPUnknownMultiple Sclerosis, Relapsing-RemittingIndia, Trinidad and Tobago
-
Charles University, Czech RepublicUnknownMyocardial Infarction
-
Pharmicell Co., Ltd.Withdrawn
-
National University of MalaysiaCytopeutics Sdn. Bhd.UnknownMiddle Cerebral Artery InfarctionMalaysia